Abbott Laboratories Issues Weak Earnings Forecast, Stocks Move Lower in Pre-Market Session

Abbott Laboratories issued a weak earnings forecast, beating EPS estimates but missing sales expectations. The company sees Q3 adjusted EPS of $1.28-$1.32, below estimates of $1.34. Abbott shares dipped 5.1% in pre-market trading. Other stocks moving lower include Nuwellis, Pitanium, Jade Biosciences, MP Materials, Ingredion, Guess?, and Standard Lithium.

Shares of Abbott Laboratories (NYSE: ABT) fell by approximately 5.1% in pre-market trading on Thursday following the company's Q3 earnings outlook, which missed sales expectations while beating EPS estimates. The North Chicago, Illinois-based healthcare giant projected its adjusted diluted earnings per share (EPS) for Q3 to range between $1.28 and $1.32, slightly below the consensus estimate of $1.33 [1]. However, the company's full-year EPS outlook of $5.10 to $5.20 remained in line with analysts' projections of $5.16 [1].

Abbott's Q3 revenue stood at $11.1 billion, representing a 7% year-over-year (YoY) growth, which exceeded the consensus estimate by $80 million. The Diagnostics division, however, underperformed, with sales declining by 1% YoY to $2.17 billion, compared to the consensus estimate of $2.21 billion [1]. The company's COVID-19 testing-related sales fell by 16% YoY to $55 million, missing the $63.5 million mark projected by analysts [1].

The Medical Devices and Nutrition segments outperformed expectations, with sales of $5.37 billion and $2.21 billion, respectively, representing 13% and 3% YoY growth compared to the consensus forecasts of $5.23 billion and $2.24 billion [1]. The diabetes products segment, in particular, contributed significantly, with sales of $1.98 billion, a 20% YoY increase, and continuous glucose monitors generating $1.9 billion with a 21% YoY growth [1].

The company's adjusted operating margin for the quarter improved by 100 basis points to 22.9%, while its adjusted EPS of $1.26 remained in line with the consensus estimate despite a 11% YoY growth [1]. For the full year, Abbott projected its adjusted operating margin to reach nearly 23.5% [1].

Abbott Laboratories also announced plans to build a manufacturing facility in the U.S. state of Georgia by 2028 to support its cardiovascular business [2]. The company's quarterly dividend of $0.59 per share was declared on June 13, 2025, and will be payable on August 15, 2025 [3].

Other stocks moving lower on Thursday include Nuwellis, Pitanium, Jade Biosciences, MP Materials, Ingredion, Guess?, and Standard Lithium [1].

References:
[1] https://seekingalpha.com/news/4468328-abbott-stock-falls-q3-outlook-misses-consensus
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3TE0Q4:0-abbott-falls-after-q3-profit-forecast-below-estimates/
[3] https://www.marketscreener.com/news/abbott-laboratories-declares-cash-dividend-quarterly-dividend-payable-on-august-15-2025-ce7c5cd9dc8cf527